Racing to replace opioids, biopharma is betting on pain drugs with a checkered past

(By Damian Garde for STAT)

It was supposed to be a $10 billion idea, one that would help wean the world off its opioid dependence and give the drug industry a bounty of lucrative new products. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.